Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Needham has recently reduced Biogen Inc (BIIB) stock to Hold rating, as announced on November 18, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the stock to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...